drugset / Trial / NCT01492543
Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer
Phase 2
Unknown
30 enrolled
Chinese Academy of Medical Sciences
Beijing Chao Yang Hospital · collabChina-Japan Friendship Hospital · collabChinese PLA General Hospital · collabHebei Tumor Hospital · collabPeking University Cancer Hospital & Institute · collabTianjin Medical University Cancer Institute and Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effectiveness and safety profile of Aiyi®(Tegafur Gimeracil Oteracil Potassium Capsule, TS-1) as a second line therapy in Chinese female patients with advanced metastatic breast cancer.
Timeline
- Start
- 2011-12
- Primary completion
- 2014-04
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tegafur-gimeracil-oteracil potassium | Small molecule | — | Oral |